164265-78-5

Basic information

• Product Name: 2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-carboxylic acid
• Synonyms: 2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-carboxylic acid
• CAS NO: 164265-78-5
• Molecular Weight: 266.259
• Mol File: 164265-78-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-carboxylic acid(164265-78-5)
• EPA Substance Registry System: 2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-carboxylic acid(164265-78-5)

Safety Data

• Hazardous Substances Data: 164265-78-5(Hazardous Substances Data)

Upstream product

• 137862-53-4 valsartan 
• 4334-88-7 p-ethoxycarbonylphenylboronic acid 
• 2042-37-7 o-cyanobromobenzene 
• 501427-88-9 2'-cyano-biphenyl-4-carboxylic acid ethyl ester 
• 135689-93-9 4-(2-Cyanophenyl)benzaldehyde 

Downstream Products

• 1240486-04-7 [Cd(2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-carboxylic acid(-2H))(H₂O)] 

Relevant articles and documents

Isolation and characterization of novel degradation products of valsartan by NMR and high resolution mass spectroscopy: Development and validation of valsartan by UPLC

Valsartan is used to treat high blood pressure, heart failure and diabetic kidney disease. It was subjected to forced degradation under acidic, basic and peroxide mediated oxidation. The forced degradation was performed according to ICH guidelines Q1A(R2)?Stability Testing of New Drug Substances and Products. The drug was inert under peroxide mediated hydrolysis, two degradants (DP-Val-1, DP-Val-2) were formed in base hydrolysis and one degradant (DP-Val-3) was formed in acid hydrolysis. These degradants were initially identified through LC-MS and isolated by mass mediated purification system. DP-Val-1 and DP-Val-3 are already reported but their structures were not confirmed by 2D NMR studies. DP-Val-2 is novel degradant and its structure has been elucidated by substantial analysis of high resolution mass spectrometry and 1D, 2D NMR spectroscopy. DP-Val-1 consists of a mixture of rotamers and this hypothesis was confirmed by variable temperature NMR (VT-NMR). A stability indicating RP-UPLC method was developed and validated for assay determination valsartan API drug. A valsartan UPLC method was validated on Acquity BEH C-18 2.1 × 100 mm, 1.7 μm column with shorter runtime of 6 min and the method was validated as per regulatory guidelines in terms of specificity, accuracy, linearity, precision, limit of detection and limit of quantitation.

2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-CARBALDEHYDE CRYSTAL AND ITS MANUFACTURING METHOD

PROBLEM TO BE SOLVED: To provide a method for industrially manufacturing 2'-(1H-tetrazol-5-yl)biphenyl-4-carbaldehyde crystal of high purity with a high yield in a short step using an inexpensive reagent. SOLUTION: The manufacturing method of 2'-(1H-tetrazol-5-yl)biphenyl-4-carbaldehyde crystal of high purity comprises a step for reacting 2'-cyanobiphenyl-4-carbaldehyde with an azide salt and a step for crystallizing the crude 2'-(1H-tetrazol-5-yl)biphenyl-4-carbaldehyde crystal obtained by the above step from tetrahydrofuran.